|
The regulatory decision is supported by data from the primary analysis of the Phase III BRUIN CLL-313 clinical study.
|
 |
|
The investment adds to more than $7bn spent by Bayer on research, development, and manufacturing in the US.
|
|
|
Ivonescimab is currently in development as a combination drug across several types of solid tumours.
|
|
|
Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.
|
|
|
In this issue: Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.
|
|
